NasdaqGS - Delayed Quote • USD
Immunic, Inc. (IMUX)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:52 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | -0.26 | -0.24 | -0.99 | -0.92 |
| Low Estimate | -0.32 | -0.25 | -1.06 | -1.15 |
| High Estimate | -0.23 | -0.22 | -0.94 | -0.71 |
| Year Ago EPS | -0.58 | -0.54 | -2.11 | -0.99 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.52 | -0.52 | -0.55 | -0.51 |
| EPS Actual | -0.58 | -0.54 | -0.51 | -0.48 |
| Difference | -0.06 | -0.02 | 0.04 | 0.03 |
| Surprise % | -11.50% | -3.80% | 7.30% | 5.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.26 | -0.24 | -0.99 | -0.92 |
| 7 Days Ago | -0.26 | -0.24 | -0.99 | -0.92 |
| 30 Days Ago | -0.26 | -0.24 | -1 | -0.92 |
| 60 Days Ago | -0.26 | -0.24 | -1 | -0.92 |
| 90 Days Ago | -0.48 | -0.46 | -1.85 | -1.97 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | IMUX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 55.20% | -- | -- | 6.50% |
| Next Qtr. | 55.60% | -- | -- | 12.00% |
| Current Year | 53.10% | -- | -- | 5.30% |
| Next Year | 7.10% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 15.50% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Brookline Capital: Buy | 4/5/2024 |
| Maintains | Wedbush: Outperform to Outperform | 10/10/2023 |
| Reiterates | Wedbush: Outperform to Outperform | 7/27/2023 |
| Downgrade | SVB Leerink: Outperform to Market Perform | 10/21/2022 |
| Maintains | Aegis Capital: Buy | 8/8/2022 |
| Maintains | SVB Leerink: Outperform | 6/3/2022 |
Related Tickers
ACET Adicet Bio, Inc.
1.6800
-7.18%
KPTI Karyopharm Therapeutics Inc.
1.0600
0.00%
ALT Altimmune, Inc.
7.26
+0.83%
GLTO Galecto, Inc.
0.7048
+5.62%
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
NRBO NeuroBo Pharmaceuticals, Inc.
3.1400
+2.61%
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
BDTX Black Diamond Therapeutics, Inc.
5.89
+15.26%
ATRA Atara Biotherapeutics, Inc.
0.6900
-1.40%
INAB IN8bio, Inc.
1.0400
0.00%